| Name | Title | Contact Details |
|---|
bioStrategies Group is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Syndax is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer (TNBC). Entinostat is an oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body`s immune response to tumors. Entinostat is being evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck and Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Merck KGaA, Darmstadt, Germany and Pfizer Inc. in ovarian cancer. Syndax is also developing entinostat as a combination therapeutic in a Phase 3 clinical trial that is being conducted with ECOG-ACRIN for advanced hormone receptor positive breast cancer.
Kratos Analytical is a Spring Valley, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Singulex is a Alameda, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Curve Biosciences (“Curve”), a company bringing precision to chronic disease care, creates products targeting biological changes in tissues that result in the development and progression of chronic diseases. Curve`s Chronic Disease Tissue Atlas (CDTA) uniquely allows the company to discover these precise changes with data from over 250,000 tissues across more than 1,000 clinical studies. Curve is focused on first commercializing its best-in-class blood tests for the $30 billion market of chronic liver diseases while using CDTA to find biomarkers and targets for other conditions.